looking for >> j and j does have three core segments in some part it dictates the way investors look at lhealthway of growth and what's happening with pharmaceuticals and devices. i think of the two segments that investors are focused on, the device and diagnostic business might be the most important. this particular quarter, just given how much we spoken about the recovery trade and procedure volume, medical utilization broadly speaking what they have to say about that not only in the quarter but commentary around how april is doing and forward looking statements with respect to that. >> i'm curious do you have a sense of where the flows are coming from. how does that play into how investors perceive this earnings season is it almost less important but maybe less important because relative to the rest of the market it seems safer? >> yeah, there's so many different varvariables at play here when we look at what's driving it, i think a lot has been broader industry safety or defensive trade that's being put on by investors that looked at many areas of this sector, pharmaceuticals and managed ca